Immunotherapy · 2022 · 42 citations · 27 references
Life SciencesImmunologyPharmacotherapyClinical ImmunologyImmunotherapyInflammationAnti-inflammatory PharmacologyCancer ImmunotherapyImmunotherapy SafetyInflammatory MediatorsMonoclonal Antibody TherapyTherapeutic Monoclonal AntibodiesAntibody Therapeutic EfficacyEgfr InhibitionImmune MarkersImmunoglobulin E Targeted TherapyMedian AgePhase Ii InvestigationProspective Trial RegistrationSars-cov-2 Infection
Background: Lung injury and STAT1 deficit induce EGFR overexpression in SARS-CoV-2 infection. Patients & methods: A phase I/II trial was done to evaluate the safety and preliminary effect of nimotuzumab, an anti-EGFR antibody, in COVID-19 patients. Patients received from one to three infusions together with other drugs included in the national guideline. Results: 41 patients (31 severe and 10 moderate) received nimotuzumab. The median age was 62 years and the main comorbidities were hypertension, diabetes and cardiovascular disease. The antibody was very safe and the 14-day recovery rate was 82.9%. Inflammatory markers decreased over time. Patients did not show signs of fibrosis. Conclusion: Nimotuzumab is a safe antibody that might reduce inflammation and prevent fibrosis in severe and moderate COVID-19 patients. Clinical Trial Registration: RPCEC00000369 (rpcec.sld.cu).
27
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
André C. Kalil, Thomas F. Patterson, Aneesh K. Mehta et al. · New England Journal of Medicine · 2020 · 1.9K citations · Full text
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
Iván O. Rosas, Norbert Bräu, Michael R. Waters et al. · New England Journal of Medicine · 2021 · 1.1K citations · Full text
Sujin Kang, Toshio Tanaka, Hitomi Inoue et al. · Proceedings of the National Academy of Sciences · 2020 · 334 citations · Full text